These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Endothelial-like progenitor cells engineered to produce prostacyclin rescue monocrotaline-induced pulmonary arterial hypertension and provide right ventricle benefits. Zhou L; Chen Z; Vanderslice P; So SP; Ruan KH; Willerson JT; Dixon RA Circulation; 2013 Aug; 128(9):982-94. PubMed ID: 23841984 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Lang IM; Gaine SP Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977 [TBL] [Abstract][Full Text] [Related]
4. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Sitbon O; Vonk Noordegraaf A Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285 [TBL] [Abstract][Full Text] [Related]
5. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Ito T; Okada T; Mimuro J; Miyashita H; Uchibori R; Urabe M; Mizukami H; Kume A; Takahashi M; Ikeda U; Sakata Y; Shimada K; Ozawa K Hypertension; 2007 Sep; 50(3):531-6. PubMed ID: 17635855 [TBL] [Abstract][Full Text] [Related]
6. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL; Michelakis ED Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [TBL] [Abstract][Full Text] [Related]
7. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Nagaya N; Yokoyama C; Kyotani S; Shimonishi M; Morishita R; Uematsu M; Nishikimi T; Nakanishi N; Ogihara T; Yamagishi M; Miyatake K; Kaneda Y; Tanabe T Circulation; 2000 Oct; 102(16):2005-10. PubMed ID: 11034952 [TBL] [Abstract][Full Text] [Related]
8. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. De Wet CJ; Affleck DG; Jacobsohn E; Avidan MS; Tymkew H; Hill LL; Zanaboni PB; Moazami N; Smith JR J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1058-67. PubMed ID: 15052203 [TBL] [Abstract][Full Text] [Related]
9. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Tahara N; Kai H; Niiyama H; Mori T; Sugi Y; Takayama N; Yasukawa H; Numaguchi Y; Matsui H; Okumura K; Imaizumi T Hum Gene Ther; 2004 Dec; 15(12):1270-8. PubMed ID: 15684702 [TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Takemiya K; Kai H; Yasukawa H; Tahara N; Kato S; Imaizumi T Basic Res Cardiol; 2010 May; 105(3):409-17. PubMed ID: 19838762 [TBL] [Abstract][Full Text] [Related]
11. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases. Cavusoglu Y; Beyaztas A; Birdane A; Ata N J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):503-7. PubMed ID: 19346968 [TBL] [Abstract][Full Text] [Related]
12. Prostacyclin therapy for pulmonary arterial hypertension: new directions. Gomberg-Maitland M; Preston IR Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316 [TBL] [Abstract][Full Text] [Related]
13. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Gildea TR; Arroliga AC; Minai OA Cleve Clin J Med; 2003 Apr; 70 Suppl 1():S18-27. PubMed ID: 12716139 [TBL] [Abstract][Full Text] [Related]
14. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost]. Matthes J; Mathen F; Herzig S; Wassermann K Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752 [No Abstract] [Full Text] [Related]
15. Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. Suhara H; Sawa Y; Fukushima N; Kagisaki K; Yokoyama C; Tanabe T; Ohtake S; Matsuda H J Thorac Cardiovasc Surg; 2002 May; 123(5):855-61. PubMed ID: 12019369 [TBL] [Abstract][Full Text] [Related]
16. Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension-a case report. Younger JR; Lui CY Angiology; 2004; 55(3):341-4. PubMed ID: 15156270 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Abston E; Moll M; Hon S; Govender P; Berman J; Farber H Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):184-191. PubMed ID: 33093782 [TBL] [Abstract][Full Text] [Related]
18. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in the treatment of pediatric pulmonary artery hypertension. Barst RJ Pediatr Clin North Am; 1999 Apr; 46(2):331-45. PubMed ID: 10218078 [TBL] [Abstract][Full Text] [Related]
20. Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension. Schroll S; Arzt M; Sebah D; Stoelcker B; Luchner A; Budweiser S; Blumberg FC; Pfeifer M Scand J Clin Lab Invest; 2008; 68(4):270-6. PubMed ID: 18612919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]